MDMA clinical trials in the registry
Data as of 31 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
MDMA (3,4-methylenedioxymethamphetamine) is a synthetic compound that registered studies often pair with structured psychological support. This page summarises registered studies whose registry records mention MDMA, using PsychoactiveMap's copy of the ClinicalTrials.gov registry.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
At a glance
- 115 registered MDMA studies are counted on this page.
By registry status
| Status | Studies | Share |
|---|---|---|
| Recruiting | 23 | 20% |
| Not yet recruiting | 5 | 4% |
| Enrolling by invitation | 3 | 3% |
| Active, not recruiting | 3 | 3% |
| Completed | 65 | 57% |
| Terminated | 4 | 3% |
| Withdrawn | 6 | 5% |
| Status not reported | 6 | 5% |
By phase
| Phase | Studies | Share |
|---|---|---|
| Early Phase 1 | 10 | 9% |
| Phase 1 | 36 | 31% |
| Phase 2 | 43 | 37% |
| Phase 3 | 7 | 6% |
| Not applicable | 11 | 10% |
| Not reported | 8 | 7% |
Countries
Country is taken from the study's linked research site. 6 of 115 records have no country on file. The top 10 countries are shown.
| Country | Studies | Share |
|---|---|---|
| United States | 63 | 55% |
| Switzerland | 27 | 23% |
| Israel | 10 | 9% |
| Canada | 7 | 6% |
| Spain | 3 | 3% |
| Netherlands | 3 | 3% |
| United Kingdom | 2 | 2% |
| Australia | 1 | 1% |
| Czechia | 1 | 1% |
| Germany | 1 | 1% |
Registry-listed start years
| Start year | Studies |
|---|---|
| 2024 and later | 38 |
| 2020 to 2023 | 32 |
| 2015 to 2019 | 12 |
| 2010 to 2014 | 20 |
| Before 2010 | 12 |
| Start date not reported | 1 |
Study design
- 107 interventional and 7 observational studies.
- Median planned or actual enrolment is 24 participants (range 2 to 1,500, across 108 records that report it).
Topics named in study titles
A keyword match on registered titles, so one study can appear under more than one topic and a study can be missed. It describes what titles mention, nothing more.
| Topic | Studies |
|---|---|
| Trauma and PTSD | 48 |
| Other substance use | 20 |
| Healthy volunteers | 12 |
| Anxiety | 4 |
| Alcohol use | 3 |
| Cancer and end of life | 2 |
| Pain and headache | 1 |
| Eating disorders | 1 |
Latest registry-listed start dates
The 25 studies with the latest start dates, shown newest first. Dates may be estimated, including future dates; a listed date does not confirm that a study started. The order is not a ranking and says nothing about quality. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.
| Registry ID | Title as registered | Status | Phase | Country | Registry dates |
|---|---|---|---|---|---|
| NCT07765693 | MDMA-AT for PTSD in Young Adults With Childhood Trauma | Not yet recruiting | Phase 2 | United States | Source start: 2026-10-31 (estimated)Source date detailsStart: 2026-10-31 (precision: day; source type: ESTIMATED; estimated) Primary completion: 2028-01-30 (precision: day; source type: ESTIMATED; estimated) Study completion: 2028-12-01 (precision: day; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:18.880Z; registry revision: 2026-08-20 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. |
| NCT07704762 | Clinical Trial of MDMA-Assisted Therapy for Military Service Members With Posttraumatic Stress Disorder | Not yet recruiting | Phase 2 | Not reported | Source start: 2026-10-01 (estimated)Source date detailsStart: 2026-10-01 (precision: day; source type: ESTIMATED; estimated) Primary completion: 2028-01-01 (precision: day; source type: ESTIMATED; estimated) Study completion: 2028-10-01 (precision: day; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:18.880Z; registry revision: 2026-07-15 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. |
| NCT07555132 | Circulating Oxytocin Changes in Response to MDMA vs. Placebo in Adult Patients With Autism Spectrum Disorder and Matched Healthy Controls | Not yet recruiting | Not applicable | Switzerland | Source start: 2026-06 (estimated) Saved start 2026-06-01 differs from reported 2026-06; the saved day is not established by this observation. Source date detailsStart: 2026-06 (precision: month; source type: ESTIMATED; estimated) Primary completion: 2028-06 (precision: month; source type: ESTIMATED; estimated) Study completion: 2028-06 (precision: month; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:18.566Z; registry revision: 2026-04-29 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. |
| NCT07542145 | MDMA Assisted Therapy for BN | Recruiting | Phase 1 | United States | Source start: 2026-05-22 (actual) Saved start 2026-05-01 differs from reported 2026-05-22; the saved day is not established by this observation. Source date detailsStart: 2026-05-22 (precision: day; source type: ACTUAL; actual) Primary completion: 2028-04-30 (precision: day; source type: ESTIMATED; estimated) Study completion: 2028-04-30 (precision: day; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:18.566Z; registry revision: 2026-06-22 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. |
| NCT07569159 | MDMA Therapy in Veterans With PTSD | Recruiting | Phase 2 | United States | Source start: 2026-06-30 (estimated) Saved start 2026-05-01 differs from reported 2026-06-30; the saved day is not established by this observation. Source date detailsStart: 2026-06-30 (precision: day; source type: ESTIMATED; estimated) Primary completion: 2027-04-01 (precision: day; source type: ESTIMATED; estimated) Study completion: 2027-08 (precision: month; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:18.566Z; registry revision: 2026-07-01 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. |
| NCT07584720 | Study of Midomafetamine in Healthy Adults | Active, not recruiting | Phase 1 | United States | Source start: 2026-04-23 (actual)Source date detailsStart: 2026-04-23 (precision: day; source type: ACTUAL; actual) Primary completion: 2026-07-23 (precision: day; source type: ESTIMATED; estimated) Study completion: 2027-02-28 (precision: day; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:18.566Z; registry revision: 2026-06-29 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. |
| NCT07118839 | MDMA-Assisted Therapy for Veterans With PTSD and Alcohol Use Disorder | Recruiting | Phase 2 | United States | Source start: 2026-05-18 (actual) Saved start 2026-04-15 differs from reported 2026-05-18; the saved day is not established by this observation. Source date detailsStart: 2026-05-18 (precision: day; source type: ACTUAL; actual) Primary completion: 2030-05-01 (precision: day; source type: ESTIMATED; estimated) Study completion: 2030-05-30 (precision: day; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:18.160Z; registry revision: 2026-06-02 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. |
| NCT05455996 | MDMA-Assisted Therapy for Stress Disorders in Healthcare Workers | Not yet recruiting | Phase 2 | United States | Source start: 2026-10 (estimated) Saved start 2026-04-01 differs from reported 2026-10; the saved day is not established by this observation. Source date detailsStart: 2026-10 (precision: month; source type: ESTIMATED; estimated) Primary completion: 2028-01 (precision: month; source type: ESTIMATED; estimated) Study completion: 2028-06 (precision: month; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:16.239Z; registry revision: 2026-05-05 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. |
| NCT06066853 | MDMA-assisted Therapy for Fibromyalgia | Recruiting | Early Phase 1 | United States | Source start: 2026-09-15 (estimated) Saved start 2026-04-01 differs from reported 2026-09-15; the saved day is not established by this observation. Source date detailsStart: 2026-09-15 (precision: day; source type: ESTIMATED; estimated) Primary completion: 2026-12 (precision: month; source type: ESTIMATED; estimated) Study completion: 2026-12 (precision: month; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:17.019Z; registry revision: 2026-08-26 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. |
| NCT03606538 | MDMA in Subjects With Moderate Hepatic Impairment and Subjects With Normal Hepatic Function | Not yet recruiting | Phase 1 | United States | Source start: 2026-03-29 (estimated)Source date detailsStart: 2026-03-29 (precision: day; source type: ESTIMATED; estimated) Primary completion: 2028-12 (precision: month; source type: ESTIMATED; estimated) Study completion: 2028-12 (precision: month; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:14.715Z; registry revision: 2024-10-30 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. |
| NCT07494214 | Acute Analgesic Effects of MDMA on Experimentally Induced Acute Pain, Hyperalgesia and Allodynia in Healthy Participants | Recruiting | Phase 1 | Switzerland | Source start: 2026-03-09 (actual)Source date detailsStart: 2026-03-09 (precision: day; source type: ACTUAL; actual) Primary completion: 2027-03-09 (precision: day; source type: ESTIMATED; estimated) Study completion: 2027-04-09 (precision: day; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:18.566Z; registry revision: 2026-03-27 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. |
| NCT04454684 | A Multi-Site Study of MDMA-Assisted Psychotherapy for Eating Disorders | Withdrawn | Phase 2 | Not reported | Source start: 2026-02 (estimated) Saved start 2026-02-01 differs from reported 2026-02; the saved day is not established by this observation. Source date detailsStart: 2026-02 (precision: month; source type: ESTIMATED; estimated) Primary completion: 2028-08-10 (precision: day; source type: ESTIMATED; estimated) Study completion: 2028-08-10 (precision: day; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:15.458Z; registry revision: 2024-10-31 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. |
| NCT07102576 | MDMA-Assisted Therapy for Mental Healthcare Providers | Recruiting | Phase 1 | United States | Source start: 2026-02-11 (actual) Saved start 2026-01-01 differs from reported 2026-02-11; the saved day is not established by this observation. Source date detailsStart: 2026-02-11 (precision: day; source type: ACTUAL; actual) Primary completion: 2029-09-21 (precision: day; source type: ESTIMATED; estimated) Study completion: 2029-12-21 (precision: day; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:18.089Z; registry revision: 2026-03-27 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. |
| NCT07288151 | MDMA-Assisted Massed Exposure Therapy for PTSD | Recruiting | Phase 2 | United States | Source start: 2026-07 (estimated) Saved start 2026-01-01 differs from reported 2026-07; the saved day is not established by this observation. Source date detailsStart: 2026-07 (precision: month; source type: ESTIMATED; estimated) Primary completion: 2030-01 (precision: month; source type: ESTIMATED; estimated) Study completion: 2030-01 (precision: month; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:18.483Z; registry revision: 2026-05-26 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. |
| NCT07469098 | Group vs Individual MDMA-Assisted Therapy for PTSD After the October 7, 2023 Events | Recruiting | Phase 2 | Israel | Source start: 2025-12-24 (actual)Source date detailsStart: 2025-12-24 (precision: day; source type: ACTUAL; actual) Primary completion: 2028-12-31 (precision: day; source type: ESTIMATED; estimated) Study completion: 2029-03-31 (precision: day; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:12.355Z; registry revision: 2026-03-13 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. |
| NCT07303907 | A Phase 2A Trial of DT402 for Autism Spectrum Disorder | Recruiting | Phase 2 | United States | Source start: 2025-12-03 (actual)Source date detailsStart: 2025-12-03 (precision: day; source type: ACTUAL; actual) Primary completion: 2027-08 (precision: month; source type: ESTIMATED; estimated) Study completion: 2027-08 (precision: month; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:18.483Z; registry revision: 2026-09-02 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. |
| NCT06989957 | Psilocybin and Methylenedioxymethamphetamine (MDMA) for Post-traumatic Stress Disorder (PTSD) | Recruiting | Phase 1 | United States | Source start: 2025-09-17 (actual)Source date detailsStart: 2025-09-17 (precision: day; source type: ACTUAL; actual) Primary completion: 2028-08 (precision: month; source type: ESTIMATED; estimated) Study completion: 2029-08 (precision: month; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:18.089Z; registry revision: 2026-09-04 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. |
| NCT05783817 | MDMA-Assisted CBT for OCD (MDMA-CBT4OCD Study) | Recruiting | Phase 2 | United States | Source start: 2025-09-10 (actual)Source date detailsStart: 2025-09-10 (precision: day; source type: ACTUAL; actual) Primary completion: 2026-12-01 (precision: day; source type: ESTIMATED; estimated) Study completion: 2026-12-01 (precision: day; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:16.639Z; registry revision: 2026-03-05 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. |
| NCT06683014 | MDMA in Borderline Personality Disorder | Recruiting | Phase 2 | United States | Source start: 2025-09-05 (actual)Source date detailsStart: 2025-09-05 (precision: day; source type: ACTUAL; actual) Primary completion: 2027-06 (precision: month; source type: ESTIMATED; estimated) Study completion: 2027-06 (precision: month; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:17.720Z; registry revision: 2026-10-22 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. |
| NCT06905652 | Comparative Acute Effects of R-MDMA and S-MDMA in Healthy Participants | Completed | Phase 1 | Switzerland | Source start: 2025-07-29 (actual)Source date detailsStart: 2025-07-29 (precision: day; source type: ACTUAL; actual) Primary completion: 2026-05-12 (precision: day; source type: ACTUAL; actual) Study completion: 2026-05-12 (precision: day; source type: ACTUAL; actual) Observation retrieved: 2026-10-31T20:06:17.780Z; registry revision: 2026-05-15 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. |
| NCT06353282 | MDMA-Assisted Psychotherapy for Treatment Resistant PTSD in Adolescents | Withdrawn | Phase 2 | United States | Source start: 2025-07-01 (estimated)Source date detailsStart: 2025-07-01 (precision: day; source type: ESTIMATED; estimated) Primary completion: 2026-01-31 (precision: day; source type: ESTIMATED; estimated) Study completion: 2026-12-31 (precision: day; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:17.349Z; registry revision: 2025-04-10 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. |
| NCT06418178 | Dose Optimization of MDMA-Assisted Therapy for PTSD | Recruiting | Phase 2 | United States | Source start: 2025-06-03 (actual)Source date detailsStart: 2025-06-03 (precision: day; source type: ACTUAL; actual) Primary completion: 2029-10 (precision: month; source type: ESTIMATED; estimated) Study completion: 2029-10 (precision: month; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:17.400Z; registry revision: 2026-10-08 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. |
| NCT06954025 | High-Intensity Inpatient MDMA-Assisted Psychotherapy for PTSD | Enrolling by invitation | Phase 2 | Netherlands | Source start: 2025-05-16 (actual)Source date detailsStart: 2025-05-16 (precision: day; source type: ACTUAL; actual) Primary completion: 2026-12 (precision: month; source type: ESTIMATED; estimated) Study completion: 2027-01 (precision: month; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:18.089Z; registry revision: 2025-07-24 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. |
| NCT06884514 | Acute Effects of MDMA Co-administration on the Response to Psilocybin in Healthy Subjects | Completed | Phase 1 | Switzerland | Source start: 2025-04-03 (actual)Source date detailsStart: 2025-04-03 (precision: day; source type: ACTUAL; actual) Primary completion: 2026-05-13 (precision: day; source type: ACTUAL; actual) Study completion: 2026-05-28 (precision: day; source type: ACTUAL; actual) Observation retrieved: 2026-10-31T20:06:17.780Z; registry revision: 2026-06-25 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. |
| NCT05770375 | Tolerability of MDMA in Schizophrenia | Recruiting | Phase 1 | United States | Source start: 2024-09-01 (actual) Saved start 2025-04-01 differs from reported 2024-09-01; the saved day is not established by this observation. Source date detailsStart: 2024-09-01 (precision: day; source type: ACTUAL; actual) Primary completion: 2027-03-01 (precision: day; source type: ESTIMATED; estimated) Study completion: 2028-03-01 (precision: day; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:16.639Z; registry revision: 2026-07-17 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. |
About this data
Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals.
Other substance hubs
Psilocybin | LSD | DMT | 5-MeO-DMT | Ayahuasca | Ketamine | Ibogaine
Registry status hubs
Recruiting | Not yet recruiting | Active, not recruiting | Enrolling by invitation | Completed | Terminated | Suspended | Withdrawn
Phase hubs
Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Phase not applicable